HIPK2 - A therapeutical target to be (re)activated for tumor suppression: Role in p53 activation and HIF-1α inhibition

Cell Cycle

Volumn 9, Issue 7, 2010, Pages 1270-1275

  Nardinocchi, Lavinia ^a,b   Puca, Rosa ^a,b   Givol, David ^c   D'Orazi, Gabriella ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Angiogenesis; Apoptosis; Chemoresistance; Chemotherapy; Gene transcription; HIF1 ; HIPK2; Hypoxia; p53; Zinc supplementation

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; VASCULOTROPIN; ZINC;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; HYPOXIA; METASTASIS; NONHUMAN; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SUPPLEMENTATION;

EID: 77951937457     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.7.11125     Document Type: Review

References (56)

1. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 1998; 273:25875-9. (Pubitemid 28475817)
2. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al. Homeodomaininteracting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nature Cell Biol 2002; 4:11-9.
3. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nature Cell Biol 2002; 4:1-10.
4. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18:6845-54.
5. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102:849-62.
6. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 2005; 280:25953-9.
7. Sombroek D, Hofmann TG. How cells switch HIPK2 on and off. Cell Death Diff 2009; 16:187-94.
8. Calzado MA, Renner F, Roscic A, Schmitz ML. HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 2007; 6:139-43.
9. Rinaldo C, Prodosmo A, Siepi F, Soddu S. HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol 2007; 85:411-8.
10. D'Orazi G, Sciulli MG, Di Stefano V, Riccioni S, Frattini M, et al. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res 2006; 12:735-41.
11. Wu Y, Zhou BP. Inflammation: A driving force speeds cancer metastasis. Cell Cycle 2009; 8:3267-73.
12. Bon G, Di Carlo S, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, et al. Negative regulation of β4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res 2009; 69:5978-86.
13. Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, et al. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochem Biophys Acta 2009; 1793:368-77.
14. Calzado MA, de la Vega L, Moller A, Bowtell DD, Schmitz ML. An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response. Nature Cell Biol 2009; 11:85-91.
15. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein kinase 2 and p53 activity and suppressing HIF-1alpha. Plos ONE 2009; 4:6819.
16. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 2004; 293:311-20.
17. Pistritto G, Puca R, Nardinocchi L, Sacchi A, D'Orazi G. HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ 2007; 14:1837-9.
18. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, et al. Reversible dysfunction of wildtype p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res 2008; 68:3707-14.
19. Cho YJ, Gorina PD, Jeffrey A, Pavletich NP. Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science 1994; 265:346-55.
20. Hainaut P, Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res 1993; 53:1739-42.
21. Joenger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007; 26:2226-42.
22. Verhaegh GW, Parat MO, Richard MJ, Hainaut P. Modulation of p53 conformation and DNA-binding activity by intracellular chelation of zinc. Mol Carcinog 1998; 21:205-14. (Pubitemid 28188878)
23. Meplan C, Richard M-J, Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 2000; 19:5227-36.
24. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 2000; 35:77-83. (Pubitemid 30137066)
25. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Molec Life Sciences 2002; 59:627-47.
26. Cherian MG, Jayasurya A, Bay B-H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mut Res 2003; 533:201-9.
27. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, et al. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res 2009; 315:67-75.
28. 2 tension. Proc Natl Acad Sci USA 1995; 92:5510-4.
29. 2 tension. Am J Physiol 1996; 271:1172-80.
30. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Nature Rev Cancer 2003; 3:721-32.
31. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12:853-9.
32. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995; 1:27-31.
33. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-80.
34. Nardinocchi L, Puca R, Sacchi A, D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitisation of chemoresistant cells to undergo apoptosis. Mol Cancer 2009; 8:1.
35. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev Biol 2007; 17:45-51.
36. Polakis P. The oncogenic activation of β-catenin. Curr Opin Genet Dev Biol 1999; 9:15-21.
37. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001; 61:6050-4. (Pubitemid 32762538)
38. Puca R, Nardinocchi L, D'Orazi G. Regulation of vascular endothelial growth factor expression by homeodomain-interacting protein kinase-2. J Exp Clin Cancer Res 2008; 27:22.
39. Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J, et al. HIPK2 represses β-catenin-mediated transcription, epidermal stem cell expansion and skin tumorigenesis. Proc Natl Acad Sci USA 2007; 104:13040-5.
40. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinal F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31.
41. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christenses JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9.
42. Choi DW, Seo YM, Kim EA, Sung KS, Ahn JW, Park SJ, et al. Ubiquitination and degradation of homeodomain-interacting protein kinase-2 by WD40 repeat/SOCS box protein WSB-1. J Biol Chem 2008; 283:4682-9.
43. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, CroneJ, et al. Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint ATM and ATR. Nat Cell Biol 2008; 10:812-24. (Pubitemid 351927710)
44. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F, et al. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 2007; 25:739-50. (Pubitemid 46341925)
45. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucl Acid Res 2009; 37:4587-602.
46. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nature Rev Cancer 2002; 2:38-47. (Pubitemid 37328806)
47. Michieli P. Hypoxia, angiogenesis and cancer therapy. Cell Cycle 2009; 8:20.
48. Beyersmann D, Haase H. Functions of zinc in signalling, proliferation and differentiation of mammalian cells. Biometals 2001; 14:331-41. (Pubitemid 34066636)
49. Gresko E, Moller A, Roscic A, Schmitz ML. Covalent modification of human homeodomain-interacting protein kinase-2 by SUMO-1 at lysine 25 affects its stability. Biochem Biophys Res Commun 2005; 329:1293-9. (Pubitemid 40568710)
50. Roscic A, Moller A, Calzado MA, Renner F, Wimmer VC, Gresko E, et al. Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol Cell 2006; 24:77-89. (Pubitemid 44466680)
51. Verger A, Perdomo J, Crossley M. Modification with SUMO: A role in transcriptional regulation. EMBO Reports 2003; 4:137-42. (Pubitemid 36322153)
52. Prasad AS, Kucuk O. Zinc in cancer prevention. Cancer and Met Rev 2002; 21:291-5.
53. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15:167-70.
54. Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor 1α down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther 2008; 7:1207-17.
55. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-61. (Pubitemid 38340304)
56. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13-7.